Laura Barker

1.1k total citations · 1 hit paper
17 papers, 478 citations indexed

About

Laura Barker is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Laura Barker has authored 17 papers receiving a total of 478 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 4 papers in Genetics. Recurrent topics in Laura Barker's work include PARP inhibition in cancer therapy (11 papers), Prostate Cancer Treatment and Research (8 papers) and Ovarian cancer diagnosis and treatment (4 papers). Laura Barker is often cited by papers focused on PARP inhibition in cancer therapy (11 papers), Prostate Cancer Treatment and Research (8 papers) and Ovarian cancer diagnosis and treatment (4 papers). Laura Barker collaborates with scholars based in United Kingdom, United States and Japan. Laura Barker's co-authors include Tsveta Milenkova, Charles A. Leath, Richard T. Penson, Sang Young Ryu, David Cibula, Radosław Mądry, Elizabeth Lowe, Mariusz Bidziński, Nicoletta Colombo and Ricardo Villalobos-Valencia and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Laura Barker

15 papers receiving 465 citations

Hit Papers

Olaparib plus abiraterone versus placebo plus abiraterone... 2023 2026 2024 2025 2023 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
    2023 132 citations Fred Saad, Noel W. Clarke et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laura Barker United Kingdom 8 330 176 159 152 93 17 478
Betül T. Yesilyurt Belgium 8 194 0.6× 89 0.5× 79 0.5× 184 1.2× 38 0.4× 9 452
Robert L. Hollis United Kingdom 15 256 0.8× 78 0.4× 431 2.7× 255 1.7× 98 1.1× 32 695
Audrey Le Formal France 8 207 0.6× 170 1.0× 112 0.7× 190 1.3× 14 0.2× 18 422
S. M. Domchek United States 8 317 1.0× 73 0.4× 80 0.5× 143 0.9× 100 1.1× 21 400
Ana T. Nunes United States 11 275 0.8× 70 0.4× 52 0.3× 120 0.8× 17 0.2× 19 455
Ahmed Kamel Egypt 5 111 0.3× 51 0.3× 123 0.8× 90 0.6× 26 0.3× 15 287
Alison Freimund Australia 8 276 0.8× 37 0.2× 126 0.8× 139 0.9× 29 0.3× 11 375
Ingirídur Skírnisdóttir Sweden 16 234 0.7× 77 0.4× 499 3.1× 176 1.2× 33 0.4× 26 682
Tabari M. Baker United States 6 265 0.8× 71 0.4× 40 0.3× 234 1.5× 63 0.7× 12 406
Seden Küçücük Türkiye 11 131 0.4× 66 0.4× 36 0.2× 103 0.7× 41 0.4× 32 322

Countries citing papers authored by Laura Barker

Since Specialization
Citations

This map shows the geographic impact of Laura Barker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Barker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Barker more than expected).

Fields of papers citing papers by Laura Barker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Barker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Barker. The network helps show where Laura Barker may publish in the future.

Co-authorship network of co-authors of Laura Barker

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Barker. A scholar is included among the top collaborators of Laura Barker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Barker. Laura Barker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Barker, Laura, Cherry Koh, Michael J. Solomon, et al.. (2025). Impact of frailty on surgical and survival outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. European Journal of Surgical Oncology. 51(10). 110323–110323.
2.
Raufi, Alexander G., Lipika Goyal, Elizabeth Smyth, et al.. (2024). CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3163–TPS3163. 3 indexed citations
3.
Saad, Fred, Andrew J. Armstrong, Karina Vianna, et al.. (2024). Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial. European Urology Oncology. 7(6). 1394–1402. 7 indexed citations
4.
5.
Armstrong, Andrew J., Noel W. Clarke, Giuseppe Procopio, et al.. (2023). Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial. European Urology Oncology. 7(2). 292–296. 1 indexed citations
6.
Saad, Fred, Noel W. Clarke, Mototsugu Oya, et al.. (2023). Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. The Lancet Oncology. 24(10). 1094–1108. 132 indexed citations breakdown →
7.
Clarke, Noel W., Andrew J. Armstrong, Antoine Thiery-Vuillemin, et al.. (2023). Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 41(6_suppl). LBA16–LBA16. 31 indexed citations
8.
9.
10.
Thiery-Vuillemin, Antoine, Fred Saad, Andrew J. Armstrong, et al.. (2022). Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.. Journal of Clinical Oncology. 40(16_suppl). 5019–5019. 2 indexed citations
11.
Armstrong, Andrew J., Noel W. Clarke, Antoine Thiery-Vuillemin, et al.. (2022). Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial.. Journal of Clinical Oncology. 40(16_suppl). 5050–5050. 2 indexed citations
12.
13.
Penson, Richard T., Ricardo Villalobos-Valencia, David Cibula, et al.. (2020). Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. Journal of Clinical Oncology. 38(11). 1164–1174. 195 indexed citations
14.
Penson, Richard T., Ricardo Villalobos-Valencia, David Cibula, et al.. (2019). Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.. Journal of Clinical Oncology. 37(15_suppl). 5506–5506. 22 indexed citations
15.
16.
Palmieri, Carlo, Richard Szydlo, Laura Barker, et al.. (2017). IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer. Breast Cancer Research and Treatment. 166(2). 527–539. 25 indexed citations
17.
Barker, Laura, et al.. (2009). Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. Current Medical Research and Opinion. 25(5). 1105–1109. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Betül T. Yesilyurt Breakdown of academic impact, for papers by Robert L. Hollis Breakdown of academic impact, for papers by Audrey Le Formal Breakdown of academic impact, for papers by S. M. Domchek Breakdown of academic impact, for papers by Ana T. Nunes Breakdown of academic impact, for papers by Ahmed Kamel Breakdown of academic impact, for papers by Alison Freimund Breakdown of academic impact, for papers by Ingirídur Skírnisdóttir Breakdown of academic impact, for papers by Tabari M. Baker Breakdown of academic impact, for papers by Seden Küçücük
Rankless by CCL
2026